ACMT will present two full-day Satellite Sessions on Thursday, April 11, preceding our Annual Scientific Meeting (April 12-14). Below is information for Legal Cannabis: Medical, Toxicological and Public Health Implications. For information on the other Satellite Session, go to: New Frontiers in Medical Toxicology: Pharmacogenomics and Precision Medicine.
Legal Cannabis: Medical, Toxicological and Public Health Implications
First Colorado and Washington, then Oregon, Hawaii, Massachusetts, Vermont, Maine, and Nevada, and now California the biggest of them all – with its 40 million people – are all states that have legalized recreational cannabis since 2012. Before this, cannabis use had been considered illicit, consumption was underground, rarely drew medical attention, and was little researched. Even today, cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act of 1970. With the sudden legalization of recreational cannabis consumption on the state level, increased cannabis use brings to the forefront a host of important medical, toxicological and public health questions.
Is it safe? How do we assess for cannabis impairment? What are the acute complications of high potency cannabis? What are the longer term adverse effects on cognitive development in teenagers? How about the problems in pregnancy and early childhood? What are the occupational hazards of cannabis cultivation? How do we develop a sound public health policy to legal recreational cannabis, and what lessons from other public health efforts such as tobacco prevention should be heeded? And finally, are there scientifically sound clinical indications for cannabis as a therapeutic agent?
This course is intended to bring together health care providers, toxicologists, public health officials, and others with an interest in learning more about the implications of legalizing cannabis use, and addressing these important issues.
Is it safe? How do we assess for cannabis impairment? What are the acute complications of high potency cannabis? What are the longer term adverse effects on cognitive development in teenagers? How about the problems in pregnancy and early childhood? What are the occupational hazards of cannabis cultivation? How do we develop a sound public health policy to legal recreational cannabis, and what lessons from other public health efforts such as tobacco prevention should be heeded? And finally, are there scientifically sound clinical indications for cannabis as a therapeutic agent?
This course is intended to bring together health care providers, toxicologists, public health officials, and others with an interest in learning more about the implications of legalizing cannabis use, and addressing these important issues.
Preliminary Agenda
| 7:00 - 7:45 AM | Registration |
| 7:45 - 8:00 AM |
Welcome & Introductions
Paul W. Wax, MD, FACMT, Executive Director, American College of Medical Toxicology
|
| 8:00 - 8:30 AM |
Public Health Regulation of Medical and Recreational Cannabis: New Approaches by California
Shelley DuTeaux, PhD, MPH, Chief, Human Health Assessment Branch, California Department of Pesticide Regulation, Sacramento, CA
|
| 8:30 - 9:00 AM |
Essential Pharmacokenetics of Cannabis and Forensic Analysis of Blood & Urine
Kara Lynch, PhD, Associate Clinical Professor, Associate Division Chief, Clinical Chemistry and Toxicology Laboratory, San Francisco General Hospital, San Francisco, CA
|
| 9:00 - 9:30 AM |
Problems and Prospects in the Use of Alternatives Matrices for Detection of Cannabis: Oral Fluid and Hair
Kara Lynch, PhD, Associate Clinical Professor, Associate Division Chief, Clinical Chemistry and Toxicology Laboratory, San Francisco General Hospital, San Francisco, CA
|
| 9:30 - 10:00 AM |
Development of a Breathalyzer for THC
Mike Lynn, MD, Emergency Physician, Alameda Health System-Highland Hospital; CEO & Co-Founder, Hound Labs, Oakland, CA
|
| 10:00 - 10:15 AM | Break |
| 10:15 - 11:00 AM |
How to Assess the Impact of Cannabis on Driving and Workplace Performance
Michael J. Kosnett, MD, MPH, FACMT, Associate Clinical Professor, University of Colorado School of Medicine, and Colorado School of Public Health, Denver, CO
|
| 11:00 - 11:15 AM |
Evaluating Cannabis Levels in a Fatal Case
Luke Rodda, PhD, Chief Forensic Toxicologist & Forensic Laboratory Division Director, San Francisco Office of the Chief Medical Examiner, San Francisco, CA
|
| 11:15 - 12:00 PM |
Impaired or Not: Challenging Cannabis Cases with Panel Discussion and Audience Participation
Moderator: Kathryn Meier, PharmD, DABAT, Clinical Pharmacist, Clinical Toxicologist, University of California San Francisco, San Francisco, CA
Neil L. Benowitz, MD, Professor of Medicine and Bioengineering & Therapeutic Sciences; Chief, Division of Clinical Pharmacology, University of California San Francisco, San Francisco, CA
Michael J. Kosnett, MD, MPH, FACMT, Associate Clinical Professor, University of Colorado School of Medicine, and Colorado School of Public Health, Denver, CO
Kara Lynch, PhD, Associate Clinical Professor, Associate Division Chief, Clinical Chemistry and Toxicology Laboratory, San Francisco General Hospital, San Francisco, CA
Mike Lynn, MD, CEO & Co-Founder, Hound Labs, Oakland, CA
Luke Rodda, PhD, Chief Forensic Toxicologist & Forensic Laboratory Division Director, San Francisco Office of the Chief Medical Examiner, San Francisco, CA
|
| 12:00 - 1:15 PM | Lunch Break |
| 1:15 - 1:45 PM |
Prenatal and Early-Childhood Exposure
Kennon Heard, MD, FACMT, FACEP, Professor of Emergency Medicine, University of Colorado School of Medicine, Denver, CO
|
| 1:45 - 2:15 PM |
Effects of Teenage Cannabis Use on Brain Development
Susan Tapert, PhD, Professor, Department of Psychiatry, University of California, San Diego, CA
|
| 2:15 - 2:45 PM |
Adverse Effects of Heavy Cannabis Use in Adults: From Hyperemesis to Heart Attack
Eike Blohm, MD, Assistant Professor, Department of Surgery, Division of Emergency Medicine, Larner College of Medicine, University of Vermont, Burlington, VT
|
| 2:45 - 3:00 PM | Break |
| 3:00 - 3:30 PM |
Therapeutic Value of Medical Cannabis for Pain and Other Conditions: What is the Medical Evidence?
Igor Grant, MD, Professor and Chair, Department of Psychiatry, University of California, San Diego School of Medicine; Director, University of California Center for Medicinal Cannabis Research (CMCR), San Diego, CA
|
| 3:30 - 4:00 PM |
Cannabis and Competitive Sports: Evidence for Effects on Recovery and Performance Enhancement
Matthew Fedoruk, PhD, Senior Managing Director of Science & Research, US Anti-Doping Agency
|
| 4:00 - 4:30 PM |
Occupational Hazards in the Cultivation and Manufacturing of Cannabis Products
Bradley King, PhD, Industrial Hygienist, CDC/NIOSH, Denver, CO
|
| 4:30 - 5:00 PM |
Public Health Approach to Cannabis Legalization
Stanton Glantz, PhD, Professor of Medicine, Division of Cardiology; the American Legacy Foundation Distinguished Professor of Tobacco Control; Director, Center for Tobacco Control Research and Education, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA
|
Event Fees
|
Early Bird Rates*
Deadline: February 1, 2019
|
Regular Rates
February 2 - April 11, 2019
|
|||
|
Registration Category
|
Satellite
|
Registration Category |
Satellite
|
|
| ACMT Member | $225 | ACMT Member | $275 | |
| Fellow-in-Training (FIT) | $175 | Fellow-in-Training (FIT) | $225 | |
| Resident** | $175 | Resident** | $225 | |
| Medical Student** | $150 | Medical Student** | $200 | |
| Specialist in Poison Information (SPI) | $175 | Specialist in Poison Information (SPI) | $225 | |
| Non-Member - Government & Military Personnel | $225 | Non-Member - Government & Military Personnel | $275 | |
| Non-Member | $300 | Non-Member | $350 | |
| Continuing Medical Education (CME) | $75 | Continuing Medical Education (CME) | $75 | |
*Early Bird Rates end at 11:59pm ET on February 1, 2019. Fees increase to the Regular Rate after this date, no exceptions.
**Proof of student and resident status is required to confirm this rate. Proof consists of a copy of your student ID or a letter from your institution’s Registrar verifying student or resident status. Documentation must be received within two weeks of registering via email to info@acmt.net or fax to (844) 226-8333. Attention: 2019 ASM.
Cancellation Policy: Cancellations received in writing on or prior to January 31, 2019 are subject to a $150 processing fee. Refunds will not be granted after January 31, 2019. Please send cancellation request to ACMT at info@acmt.net, or fax to 623-533-6520.
Consent to Use of Photographic Images: Registration and attendance at, or participation in, ACMT meetings and other activities constitutes an agreement by the registrant to ACMT's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions and audiotapes of such events and activities.
Continuing Medical Education (CME)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Alabama School of Medicine and the American College of Medical Toxicology. The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Medical Education (CME) is pending for this activity. It is expected that the University of Alabama School of Medicine will designate this live activity for: 7.25 AMA PRA Category 1 credit(s)™
Questions?
Write to: info@acmt.net